John Timberlake has been commercializing diabetes drugs and devices for 25 years. Over the course of his career, one theme has always stood out: if you want people to use your product, it has to be made with the end-user in mind. “It’s really [about] understanding the patient first and then designing the technology around […]
tandemdiabetes
Tandem Diabetes Q3 sales top The Street
Tandem Diabetes Care (NSDQ:TNDM) today posted third quarter earnings and lifted its sales guidance for the year, beating Wall Street expectations for sales but falling behind on losses-per-share. The San Diego-based company posted losses of $34.2 million, or 62¢ per share, on sales of $46.3 million for the three months ended September 30, seeing losses grow […]
Tandem wins approval for insulin pump in Canada
Tandem Diabetes Care (NSDQ:TNDM) won a medical device license from Health Canada last week for its t:slim X2 insulin pump. The device integrates directly with Dexcom‘s (NSDQ:DXCM) G5 continuous glucose monitor and is the only system of its kind approved in Canada, according to the San Diego, Calif.-based company. Get the full story at our sister site, […]
Tandem lifts full-year sales guidance
Tandem Diabetes Care (NSDQ:TNDM) increased its full-year sales guidance, citing strong U.S. sales in the third quarter and the launch of its t:slim X2 insulin pump in international markets. The company increased its 2018 sales guidance from $140 million – $148 million to $150 million – $158 million. If Tandem posts sales within its newly-revised range, […]
Tandem launches insulin pump with predictive low glucose suspend feature in US
Tandem Diabetes Care (NSDQ:TNDM) last week launched its t:slim X2 insulin pump with Basal-IQ technology in the U.S. The company’s latest pump includes a predictive low glucose suspend feature designed to reduce the frequency and duration of hypoglycemia. Get the full story at our sister site, Drug Delivery Business News.
Tandem reels in $115m from public offering
Tandem Diabetes Care (NSDQ:TNDM) said today that it raised roughly $115 million from an underwritten public offering. The San Diego, Calif.-based company offered 3,508,770 shares of its common stock at $28.50 apiece. Underwriters fully exercised an option to buy 526,315 additional shares of common stock, Tandem noted. Get the full story at our sister site, Drug […]
Tandem prices $100m offering
Tandem Diabetes Care (NSDQ:TNDM) has priced an underwritten public offering of 3.5 million shares of common stock at $28.50 apiece. The San Diego, Calif.-based company expects to reel in roughly $100 million in gross proceeds from the offering. Tandem also gave underwriters a 30-day option to buy up to 526,315 additional shares of common stock. Get […]
Tandem posts mixed Q2 results
Shares in Tandem Diabetes Care (NSDQ:TNDM) fell this week after the insulin pump maker topped sales expectations but missed earnings estimates on Wall Street with its second-quarter financial results. The San Diego, Calif.-based company posted a net loss of -$59.4 million on sales of $34.1 million for the 3 months ended June 30, for sales growth of 60% […]
Tandem wins FDA nod for insulin pump with predictive low glucose suspend feature
The FDA this week approved Tandem Diabetes Care‘s (NSDQ:TNDM) t:slim X2 insulin pump with a predictive low glucose suspend feature designed to cut the frequency and duration of hypoglycemia. The San Diego, Calif.-based company said that upon launch, its new product will also feature Dexcom‘s (NSDQ:DXCM) G6 continuous glucose monitoring system. Tandem expects that the latest iteration of […]
Tandem wins CE Mark for t:slim X2 insulin pump
Tandem Diabetes Care (NSDQ:TNDM) said today that its t:slim X2 insulin pump won CE Mark clearance in the European Union. The San Diego, Calif.-based company plans to start selling the device in international markets in the second half of 2018. Tandem’s latest drug-pump won FDA approval in August last year. Get the full story at our […]
Sales for Tandem Diabetes Care climb 44% in Q1
Shares in Tandem Diabetes Care (NSDQ:TNDM) fell -3% today after the insulin pump maker topped revenue expectations, but missed earnings estimates on Wall Street with its first-quarter results. The San Diego, Calif.-based company posted a net loss of -$32.7 million, or -$1.82 per share, on sales of $27.3 million for the 3 months ended March 31, for […]